Leerink Partners Initiates Coverage On Neurogene with Outperform Rating, Announces Price Target of $46
Neurogene, Inc. - Common Stock -5.11%
Neurogene, Inc. - Common Stock NGNE | 49.97 | -5.11% |
Leerink Partners analyst Mani Foroohar initiates coverage on Neurogene (NASDAQ:
NGNE) with a Outperform rating and announces Price Target of $46.